Major moves in pharma and biotech partnering are reshaping the landscape. For ADC companies, the challenge lies in standing out, validating their offerings, and securing clinical-ready assets ...
At the ADC Asia Congress 2025 held today (3/12) in Singapore, OBI Pharma (4174.TWO) was honored with the "Most Promising ADC Clinical Candidate in Taiwan" award. This recognition follows OBI Pharma’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback